Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Other Non-Current Liabilities (2016 - 2025)

Moleculin Biotech's Other Non-Current Liabilities history spans 10 years, with the latest figure at $44000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Liabilities at $44000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $44000.0 (changed N/A YoY), and the annual figure for FY2025 was $44000.0, changed.
  • Other Non-Current Liabilities for Q4 2025 was $44000.0 at Moleculin Biotech, down from $41.3 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $41.3 million in Q3 2025 to a low of $1000.0 in Q3 2023.
  • The 5-year median for Other Non-Current Liabilities is $1.6 million (2021), against an average of $5.4 million.
  • The sharpest move saw Other Non-Current Liabilities tumbled 99.69% in 2023, then surged 993100.0% in 2024.
  • Year by year, Other Non-Current Liabilities stood at $1.4 million in 2021, then tumbled by 94.55% to $77000.0 in 2022, then skyrocketed by 6205.19% to $4.9 million in 2023, then soared by 104.57% to $9.9 million in 2024, then plummeted by 99.56% to $44000.0 in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $44000.0, $41.3 million, and $17.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.